Cargando…

Interferon-induced transmembrane protein 3 in hepatocellular carcinoma patients

OBJECTIVE: The study aimed to investigate the over expression of IFITM3 in hepatocellular carcinoma Egyptian patients. BACKGROUND: Hepatocellular carcinoma (HCC) continues to be a serious disease burden. Interferon Induced Transmembrane protein 3 (IFITM3) is a protein that encoded in humans by the I...

Descripción completa

Detalles Bibliográficos
Autores principales: Bondok, Rania M., Barakat, Lamiaa A., Elsergany, Alyaa R., Mahsoub, Nancy, Ghattas, Maivel H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290370/
https://www.ncbi.nlm.nih.gov/pubmed/37353775
http://dx.doi.org/10.1186/s12885-023-11071-2
_version_ 1785062481389944832
author Bondok, Rania M.
Barakat, Lamiaa A.
Elsergany, Alyaa R.
Mahsoub, Nancy
Ghattas, Maivel H.
author_facet Bondok, Rania M.
Barakat, Lamiaa A.
Elsergany, Alyaa R.
Mahsoub, Nancy
Ghattas, Maivel H.
author_sort Bondok, Rania M.
collection PubMed
description OBJECTIVE: The study aimed to investigate the over expression of IFITM3 in hepatocellular carcinoma Egyptian patients. BACKGROUND: Hepatocellular carcinoma (HCC) continues to be a serious disease burden. Interferon Induced Transmembrane protein 3 (IFITM3) is a protein that encoded in humans by the IFITM3 gene. It plays a critical role in the immune system’s defense, responsible for a large portion of the antiviral activity. In this study, we showed that IFITM3 rs 12252-CC was over expressed in HCC patients compared to control group with HCV infection. METHOD: DNA sequencing was applied for detection of IFITM3 rs 12252-CC and IFITM3 protein level was measured by ELISA to 50 patients with HCC with cirrhosis and 50 with Hepatitis C virus infection. RESULTS: The obtained results of this study indicated that IFITM3 rs 12252-CC was significantly elevated in HCC group, the codominant model of CC genotype of IFITM3 gene had high association with risk of hepatocellular carcinoma with odd ratio (OR) = 2.70, p = 0.041. CONCLUSION: IFITM3 play an important role in progression of hepatocellular carcinoma. Results revealed that IFITM3 rs 12252-CC among Hepatocellular carcinoma patients would allow diagnosis and starting intervention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11071-2.
format Online
Article
Text
id pubmed-10290370
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102903702023-06-25 Interferon-induced transmembrane protein 3 in hepatocellular carcinoma patients Bondok, Rania M. Barakat, Lamiaa A. Elsergany, Alyaa R. Mahsoub, Nancy Ghattas, Maivel H. BMC Cancer Research OBJECTIVE: The study aimed to investigate the over expression of IFITM3 in hepatocellular carcinoma Egyptian patients. BACKGROUND: Hepatocellular carcinoma (HCC) continues to be a serious disease burden. Interferon Induced Transmembrane protein 3 (IFITM3) is a protein that encoded in humans by the IFITM3 gene. It plays a critical role in the immune system’s defense, responsible for a large portion of the antiviral activity. In this study, we showed that IFITM3 rs 12252-CC was over expressed in HCC patients compared to control group with HCV infection. METHOD: DNA sequencing was applied for detection of IFITM3 rs 12252-CC and IFITM3 protein level was measured by ELISA to 50 patients with HCC with cirrhosis and 50 with Hepatitis C virus infection. RESULTS: The obtained results of this study indicated that IFITM3 rs 12252-CC was significantly elevated in HCC group, the codominant model of CC genotype of IFITM3 gene had high association with risk of hepatocellular carcinoma with odd ratio (OR) = 2.70, p = 0.041. CONCLUSION: IFITM3 play an important role in progression of hepatocellular carcinoma. Results revealed that IFITM3 rs 12252-CC among Hepatocellular carcinoma patients would allow diagnosis and starting intervention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11071-2. BioMed Central 2023-06-23 /pmc/articles/PMC10290370/ /pubmed/37353775 http://dx.doi.org/10.1186/s12885-023-11071-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bondok, Rania M.
Barakat, Lamiaa A.
Elsergany, Alyaa R.
Mahsoub, Nancy
Ghattas, Maivel H.
Interferon-induced transmembrane protein 3 in hepatocellular carcinoma patients
title Interferon-induced transmembrane protein 3 in hepatocellular carcinoma patients
title_full Interferon-induced transmembrane protein 3 in hepatocellular carcinoma patients
title_fullStr Interferon-induced transmembrane protein 3 in hepatocellular carcinoma patients
title_full_unstemmed Interferon-induced transmembrane protein 3 in hepatocellular carcinoma patients
title_short Interferon-induced transmembrane protein 3 in hepatocellular carcinoma patients
title_sort interferon-induced transmembrane protein 3 in hepatocellular carcinoma patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290370/
https://www.ncbi.nlm.nih.gov/pubmed/37353775
http://dx.doi.org/10.1186/s12885-023-11071-2
work_keys_str_mv AT bondokraniam interferoninducedtransmembraneprotein3inhepatocellularcarcinomapatients
AT barakatlamiaaa interferoninducedtransmembraneprotein3inhepatocellularcarcinomapatients
AT elserganyalyaar interferoninducedtransmembraneprotein3inhepatocellularcarcinomapatients
AT mahsoubnancy interferoninducedtransmembraneprotein3inhepatocellularcarcinomapatients
AT ghattasmaivelh interferoninducedtransmembraneprotein3inhepatocellularcarcinomapatients